ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 1103

Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study

Matthew Baker1, Claire Cook2, Xiaoqing Fu3, Cory Perugino3, John Stone4 and Zachary Wallace5, 1Stanford University, Menlo Park, CA, 2Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Newton, MA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: Biomarkers, classification criteria, IgG4 Related Disease

Session Information

Date: Monday, November 8, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Serum IgG4 concentrations are used as part of the evaluation for suspected IgG4-related disease (IgG4-RD), but the specificity of this test, especially at very high levels, remains uncertain. Indeed, the ACR/EULAR Classification Criteria for IgG4-RD place high weight on elevated serum IgG4 concentrations; of the 20 points required to be classified as IgG4-RD, 11 are assigned if the patient has an IgG4 concentration ≥ 5x the upper limit of normal (ULN).1 We sought to evaluate the association of very high serum IgG4 concentrations with a diagnosis of IgG4-RD.

Methods: The data warehouses at two large academic medical centers—Stanford University and Mass General Brigham—were queried for all IgG subclass test results. Patients with any serum IgG4 concentration ≥ 5x the ULN were included. Demographics, medical history, and other laboratory test results of interest were extracted from the electronic medical record of each patient. A diagnosis of IgG4-RD was determined using the ACR/EULAR Classification Criteria for IgG4-RD. The positive predictive value (PPV) of a serum IgG4 concentration ≥ 5x the ULN for the diagnosis of IgG4-RD was estimated. Other conditions associated with very high serum IgG4 concentrations, and specific features of the IgG4-RD patients, were characterized.

Results: Of 34,391 patients with serum IgG subclasses tested, 2,294 (7%) had an elevated serum IgG4 concentration, and 191 (0.6%) had an IgG4 concentration ≥ 5x the ULN. The combined cohort had a median age of 66 years, was predominately male (72%), and was racially diverse (Table 1). The PPV of an IgG4 concentration ≥ 5x the ULN for a diagnosis of definite (67%), probable (5%), or atypical (1%) IgG4-RD was 73%. The median [IQR] IgG4 concentration among patients with definite IgG4-RD (n = 128) was 1014.5 mg/dL [678.5, 1419.9] (Table 2). Other diseases associated with a very elevated serum IgG4 concentration included B cell lymphoma and leukemia, eosinophilic granulomatosis with polyangiitis and other hypereosinophilic syndromes, systemic lupus erythematosus, histiocytic disease, and systemic infections or post-infectious syndromes (Table 2). Among IgG4-RD patients with an IgG4 concentration ≥ 5x the ULN, the majority (82%) had multi-organ involvement, with the pancreas (50%), salivary glands (49%), lacrimal glands (33%), and kidneys (30%) being the most commonly involved organs (Table 3).

Conclusion: The majority of patients with a serum IgG4 concentration ≥ 5x the ULN in this study had IgG4-RD, with a PPV of 73% for IgG4-RD. These data support the significant weight placed on very elevated serum IgG4 in the IgG4-RD Classification Criteria. However, it is notable that 27% of patients with an IgG4 concentration ≥ 5x the ULN had no identifiable cause or an alternative diagnosis, underscoring the importance of the Classification Criteria’s entry and exclusion criteria when evaluating a patient with a very high IgG4 concentration for IgG4-RD. These findings highlight the broad differential to consider when evaluating a patient with a very high IgG4 concentration.

References:

1. Wallace ZS, Naden RP, Chari S, et al., Arthritis Rheumatol 72, 7-19 (2020).

Table 1. Demographics and clinical characteristics of patients with a serum IgG4 level >5x ULN.

Table 2. Distribution of patients with a serum IgG4 level >5x ULN by disorder.

Table 3. Manifestations of IgG4-RD in patients with a serum IgG4 level >5x ULN.


Disclosures: M. Baker, Vorso Corp, 2; C. Cook, None; X. Fu, None; C. Perugino, Viela Bio, 2; J. Stone, Principia Biopharma Inc, a Sanofi Company, 5, 12, personal fees; Z. Wallace, Bristol-Myers Squibb, 5, Principia/Sanofi, 5, Viela Bio, 2, MedPace, 2.

To cite this abstract in AMA style:

Baker M, Cook C, Fu X, Perugino C, Stone J, Wallace Z. Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/disease-associations-with-very-high-serum-igg4-concentrations-a-retrospective-multi-center-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-associations-with-very-high-serum-igg4-concentrations-a-retrospective-multi-center-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology